KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Invested Capital (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Invested Capital data on record, last reported at $421.3 million in Q4 2025.

  • For Q4 2025, Invested Capital rose 3889.51% year-over-year to $421.3 million; the TTM value through Dec 2025 reached $421.3 million, up 3889.51%, while the annual FY2025 figure was $421.3 million, 3889.51% up from the prior year.
  • Invested Capital reached $421.3 million in Q4 2025 per RIGL's latest filing, up from $147.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $421.3 million in Q4 2025 and bottomed at -$31.8 million in Q3 2023.
  • Average Invested Capital over 5 years is $37.3 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Invested Capital: plummeted 664.62% in 2023, then surged 3889.51% in 2025.
  • A 5-year view of Invested Capital shows it stood at $30.4 million in 2021, then plummeted by 144.83% to -$13.6 million in 2022, then plummeted by 57.28% to -$21.4 million in 2023, then surged by 149.31% to $10.6 million in 2024, then soared by 3889.51% to $421.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $421.3 million in Q4 2025, $147.4 million in Q3 2025, and $104.3 million in Q2 2025.